AlloCOVID is a platform intended to "inform and ensure real-time monitoring of the epidemic thanks to artificial intelligence", seven days a week and 24 hours a day. People wishing to check if they require special attention can now contact 0 806 800 540.

Researchers from Inserm and the University of Paris Monday launched a national issue, AlloCOVID, intended to "inform and ensure real-time monitoring of the epidemic thanks to artificial intelligence", seven days a week and 24 24 hours a day People over the age of 15 wishing to check whether their health profile or condition requires special attention can now contact AlloCOVID on 0 806 800 540 at the cost of a normal call, "as many times as their condition requires ", said a press release.

>> LIVE -  Coronavirus: follow the evolution of the situation on Monday, April 27

"They will then be put in contact with an 'intelligent' virtual agent, capable of synthesizing the medical information transmitted and guiding them on their susceptibility to being reached or not by the Covid-19", he adds, adding that the service was "free". The digital assistant is also able to "detect the signs of severity of the disease, as well as vulnerable patients requiring special attention," he said.

Data protection specialists participated

This device also makes it possible to optimize the collection of data to ensure real-time monitoring of the epidemic everywhere in France, DOM-COM included, adds the press release, in particular to "support the release from confinement and detect immediately potential centers of resurgence, in a synergistic and complementary way to existing devices (maladiecoronavirus.fr, SOS doctors, Sentinel network, etc.) centralized by Public Health France ", and to whom all the data collected by AlloCOVID will be communicated daily" anonymized. "

>> PODCAST -  Coronavirus: find all the answers to your questions here

In accordance with CNIL recommendations, this project was supported by data protection specialists while "the visualization and analysis of the data collected will be ensured through collaboration between Inserm and e.Voyageurs SNCF", a subsidiary of the SNCF. AlloCOVID was made available to SAMU-78 and tested for seven days during the month of April, before being extended to the national territory from Monday.